Taking On Challenges And Growing? – Arrowhead Pharmaceuticals Inc (ARWR)

After Hours

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours.

Stocks Info

This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. The current market capitalization of Arrowhead Pharmaceuticals Inc is $2.75B. A total of 2.76 million shares were traded on the day, compared to an average of 1.93M shares.

In the most recent transaction, Hamilton James C sold 9,389 shares of ARWR for 20.00 per share on Aug 15 ’25. After the transaction, the Chief Medical Officer now owns 262,122 company shares. In a previous transaction on Aug 13 ’25, Hamilton James C sold 611 shares at 20.00 per share. ARWR shares that Chief Medical Officer owns now total 271,511.

Among the insiders who bought shares, Hamilton James C acquired of 9,389 shares on Aug 15 ’25 at a per-share price of $20.00. In another insider transaction, Sarepta Therapeutics, Inc. bought 9,265,312 shares at $19.99 per share on Aug 13 ’25.

Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. In terms of 52-week highs and lows, ARWR has a high of $27.34 and a low of $9.57.

As of this writing, ARWR has an earnings estimate of -$0.21 per share for the current quarter. EPS was calculated based on a consensus of 13.0 estimates, with a high estimate of $0.69 per share and a lower estimate of -$1.18. The company reported an EPS of -$1.37 in the last quarter

Balance Sheet Annually/Quarterly

In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. ARWR’s latest balance sheet shows that the firm has $367.79M in Cash & Short Term Investments as of fiscal 2021. There were $25.55M in debt and $146.54M in liabilities at the time. Its Book Value Per Share was $3.78, while its Total Shareholder’s Equity was $408.82M.

Analysts Opinion

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ARWR is Buy with a score of 4.27.

Related Posts

Park Telegraph
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.